Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy.

Related Articles

Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy.

Int J Mol Sci. 2016 Sep 07;17(9):

Authors: Bolinger MT, Antonetti DA

Abstract
Diabetic retinopathy is the leading cause of blindness in working age adults, and is projected to be a significant future health concern due to the rising incidence of diabetes. The recent advent of anti-vascular endothelial growth factor (VEGF) antibodies has revolutionized the treatment of diabetic retinopathy but a significant subset of patients fail to respond to treatment. Accumulating evidence indicates that inflammatory cytokines and chemokines other than VEGF may contribute to the disease process. The current review examines the presence of non-VEGF cytokines in the eyes of patients with diabetic retinopathy and highlights mechanistic pathways in relevant animal models. Finally, novel drug targets including components of the kinin-kallikrein system and emerging treatments such as anti-HPTP (human protein tyrosine phosphatase) β antibodies are discussed. Recognition of non-VEGF contributions to disease pathogenesis may lead to novel therapeutics to enhance existing treatments for patients who do not respond to anti-VEGF therapies.

PMID: 27618014 [PubMed - indexed for MEDLINE]

http://ift.tt/2omDOVD